Steve Braunstein

Dr. Steve Braunstein

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PSPaul W. Sperduto
Paul W. Sperduto
SMShane Mesko
Shane Mesko
JLJing Li
Jing Li
DCDaniel Cagney
Daniel Cagney
AAAyal Aizer
Ayal Aizer
MMMinesh p Mehta
Minesh p Mehta
PURPOSE: Conventional wisdom has rendered patients with brain metastases ineligible for clinical trials for fear that poor survival could mask the benefit of otherwise promising treatments. Our group previously published the diagnosis-specific Graded Prognostic Assessment (GPA). Updates with larger contemporary cohorts using molecular markers and newly identified prognostic factors have been published. The purposes of this work are to present all the updated indices in a single report to guide treatment choice, stratify research, and define an eligibility quotient to expand eligibility. METHODS: A multi-institutional database of 6,984 patients with newly diagnosed brain metastases underwent multivariable analyses of prognostic factors and treatments associated with survival for each primary site. Significant factors were used to define the updated GPA. GPAs of 4.0 and 0.0 correlate with the best and worst prognoses, respectively. RESULTS: Significant prognostic factors varied by diagnosis and new prognostic factors were identified. Those factors were incorporated into the updated GPA with robust separation ( P < .01) between subgroups. Survival has improved, but varies widely by GPA for patients with non–small-cell lung, breast, melanoma, GI, and renal cancer with brain metastases from 7-47 months, 3-36 months, 5-34 months, 3-17 months, and 4-35 months, respectively. CONCLUSION: Median survival varies widely and our ability to estimate survival for patients with brain metastases has improved. The updated GPA (available free at brainmetgpa.com) provides an accurate tool with which to estimate survival, individualize treatment, and stratify clinical trials. Instead of excluding patients with brain metastases, enrollment should be encouraged and those trials should be stratified by the GPA to ensure those trials make appropriate comparisons. Furthermore, we recommend the expansion of eligibility to allow for the enrollment of patients with previously treated brain metastases who have a 50% or greater probability of an additional year of survival (eligibility quotient > 0.50).

29 March 2017 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
SBSteve Braunstein
Steve Braunstein
DRDavid Raleigh
David Raleigh
RBRanjit Bindra
Ranjit Bindra
SMSabine Mueller
Sabine Mueller
DHDaphne Haas-Kogan
Daphne Haas-Kogan

1 November 2018 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
OMOlivier Morin
Olivier Morin
MVMartin Vallières
Martin Vallières
AJArthur Jochems
Arthur Jochems
HWHenry C. Woodruff
Henry C. Woodruff
GVGilmer Valdes
Gilmer Valdes
PLPhilippe Lambin
Philippe Lambin

23 March 2019 in BMC Palliative Care
Verified
Journal Article
Open access
PDF file
SWSusan Y. Wu
Susan Y. Wu
LSLisa Singer
Lisa Singer
LBLauren Boreta
Lauren Boreta
MGMichael A. Garcia
Michael A. Garcia
SFShannon E. Fogh
Shannon E. Fogh
SBSteve Braunstein
Steve Braunstein
A significant proportion of patients with advanced cancer undergo palliative radiotherapy (RT) within their last 30 days of life. This study characterizes palliative RT at our institution and aims to identify patients who may experience limited benefit from RT due to imminent mortality. Five hundred and-eighteen patients treated with external beam RT to a site of metastatic disease between 2012 and 2016 were included. Mann-Whitney U and chi-squared tests were used to identify factors associated with RT within 30 days of death (D30RT). Median age at RT was 63 years (IQR 54–71). Median time from RT to death was 74 days (IQR 33–174). One hundred and twenty-five patients (24%) died within 30 days of RT. D30RT was associated with older age at RT (64 vs. 62 years, p = 0.04), shorter interval since diagnosis (14 vs. 31 months, p < 0.001), liver metastasis (p = 0.02), lower KPS (50 vs. 70, p < 0.001), lower BMI (22 vs. 24, p = 0.001), and inpatient status at consult (56% vs. 26%, p < 0.001). Patients who died within 30 days of RT were less likely to have hospice involved in their care (44% vs. 71%, p = 0.001). D30RT was associated with higher Chow and TEACHH scores at consult (p < 0.001 for both). Twenty-four percent of patients received palliative RT within 30 days of death. Additional tools are necessary to help physicians identify patients who would benefit from short treatment courses or alternative interventions to maximize quality at the end of life.

20 October 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LPLuke R.G. Pike
Luke R.G. Pike
EMEmily Miao
Emily Miao
LBLillian A. Boe
Lillian A. Boe
TPTejas Patil
Tejas Patil
BIBrandon S. Imber
Brandon S. Imber
CRChad G. Rusthoven
Chad G. Rusthoven
PURPOSE: Newer-generation tyrosine kinase inhibitors (TKIs) for non–small cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR ) mutations and anaplastic lymphoma kinase ( ALK ) rearrangements have demonstrated high CNS activity. The optimal use of up-front stereotactic radiosurgery (SRS) for brain metastases (BM) in patients eligible for CNS-penetrant TKIs is controversial, and data to guide patient management are limited. MATERIALS AND METHODS: Data on TKI-naïve patients with EGFR- and ALK-driven NSCLC with BM treated with CNS-penetrant TKIs with and without up-front SRS were retrospectively collected from seven academic centers in the United States. Time-to-CNS progression and overall survival (OS) were analyzed, with multivariable adjustment in Fine & Gray and Cox proportional hazards models for clinically relevant factors. RESULTS: From 2013 to 2022, 317 patients were identified (200 TKI-only and 117 TKI + SRS). Two hundred fifty (79%) and 61 (19%) patients received osimertinib and alectinib, respectively. Patients receiving TKI + SRS were more likely to have BM ≥1 cm ( P < .001) and neurologic symptoms ( P < .001) at presentation. Median OS was similar between the TKI and TKI + SRS groups (median 41 v 40 months, respectively; P = .5). On multivariable analysis, TKI + SRS was associated with a significant improvement in time-to-CNS progression (hazard ratio [HR], 0.63 [95% CI, 0.42 to 0.96]; P = .033). Local CNS control was significantly improved with TKI + SRS (HR, 0.30 [95% CI, 0.16 to 0.55]; P < .001), whereas no significant differences were observed in distant CNS control. Subgroup analyses demonstrated a greater benefit from TKI + SRS in patients with BM ≥1 cm in diameter for time-to-CNS progression and CNS progression-free survival. CONCLUSION: The addition of up-front SRS to CNS-penetrant TKI improved time-to-CNS progression and local CNS control, but not OS, in patients with BM from EGFR - and ALK-driven NSCLC. Patients with larger BM (≥1 cm) may benefit the most from up-front SRS.

13 May 2021 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
WCWilliam C. Chen
William C. Chen
UBUlysis H. Baal
Ulysis H. Baal
JBJoe D. Baal
Joe D. Baal
JPJon S. Pai
Jon S. Pai
LBLauren Boreta
Lauren Boreta
DRDavid R. Raleigh
David R. Raleigh
Quiz Ref ID Brainstem metastases (BSM) represent 4% to 7% of all secondary intracranial tumors1-4 but are not amenable to resection owing to a high risk of morbidity or mortality from damage to critical neurologic structures. Stereotactic radiosurgery (SRS) is an effective treatment for nonbrainstem brain metastases (BM) that does not cause the neurocognitive deficits of whole-brain radiotherapy (WBRT).5 Nearly all prospective trials of SRS for BM have excluded patients with BSM.5-10 Thus, reports of SRS for BSM are limited to small retrospective series,11-43 and the efficacy and safety of SRS for BSM are incompletely understood. To address this unmet need, we performed a quantitative meta-analysis of SRS for BSM to estimate pooled measures of efficacy and safety in the context of prospective trials of SRS or molecular therapy for nonbrainstem BM.